CN101103033B - 作为pde2抑制剂的***并酞嗪 - Google Patents
作为pde2抑制剂的***并酞嗪 Download PDFInfo
- Publication number
- CN101103033B CN101103033B CN2006800017646A CN200680001764A CN101103033B CN 101103033 B CN101103033 B CN 101103033B CN 2006800017646 A CN2006800017646 A CN 2006800017646A CN 200680001764 A CN200680001764 A CN 200680001764A CN 101103033 B CN101103033 B CN 101103033B
- Authority
- CN
- China
- Prior art keywords
- phenyl
- alkyl
- base
- group
- phthalazines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
Abstract
Description
化合物 | -log IC50[mol/l] |
1到22、25到28、29到35、37、38、T1到T9 | 这些列出的化合物的抑制值的范围在6.0到10.0之间 |
化合物 | -log IC50[mol/l] |
1、3、4、6、7、9、10、13、14、15、17、19、21、22、25到28;29到34 | 这些列出的化合物的抑制值在6.9到9.3之间 |
Claims (19)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05100045 | 2005-01-05 | ||
EP05100044 | 2005-01-05 | ||
EP05100045.3 | 2005-01-05 | ||
EP05100044.6 | 2005-01-05 | ||
PCT/EP2006/050041 WO2006072615A2 (en) | 2005-01-05 | 2006-01-04 | Triazolophthalazines as pde2-inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101103033A CN101103033A (zh) | 2008-01-09 |
CN101103033B true CN101103033B (zh) | 2010-08-04 |
Family
ID=36604687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006800017646A Expired - Fee Related CN101103033B (zh) | 2005-01-05 | 2006-01-04 | 作为pde2抑制剂的***并酞嗪 |
Country Status (16)
Country | Link |
---|---|
US (1) | US8106047B2 (zh) |
EP (1) | EP1836207B1 (zh) |
JP (1) | JP5240899B2 (zh) |
KR (1) | KR20070095986A (zh) |
CN (1) | CN101103033B (zh) |
AU (1) | AU2006204454B2 (zh) |
BR (1) | BRPI0606379A2 (zh) |
CA (1) | CA2592007C (zh) |
EA (1) | EA012505B1 (zh) |
ES (1) | ES2397080T3 (zh) |
HK (1) | HK1116776A1 (zh) |
IL (1) | IL183919A (zh) |
MX (1) | MX2007008137A (zh) |
NO (1) | NO20073921L (zh) |
NZ (1) | NZ555661A (zh) |
WO (1) | WO2006072615A2 (zh) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101368093B1 (ko) * | 2004-09-02 | 2014-03-14 | 다케다 게엠베하 | 트리아졸로프탈라진 |
CA2591991C (en) | 2005-01-05 | 2013-11-19 | Altana Pharma Ag | Triazolophthalazines |
KR20070095986A (ko) | 2005-01-05 | 2007-10-01 | 니코메드 게엠베하 | Pde2 억제제로서의 트리아졸로프탈라진 |
AU2010338038B2 (en) | 2009-12-31 | 2015-07-09 | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Tricyclic compounds for use as kinase inhibitors |
US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
MX2013014470A (es) * | 2011-06-07 | 2014-03-21 | Pfizer | Compuestos de pirazolo[3,4-d]pirimidina y su uso como inhibidores pde2 y/o inhibidores cyp3a4. |
CA2869730A1 (en) | 2012-04-25 | 2013-10-31 | Takeda Pharmaceutical Company Limited | Nitrogenated heterocyclic compound |
EP2844660B1 (en) | 2012-05-02 | 2017-11-01 | Southern Research Institute | Triazolopyridazine compounds, use as inhibitors of the kinase lrrk2, and methods for preparation thereof |
WO2014010732A1 (ja) * | 2012-07-13 | 2014-01-16 | 武田薬品工業株式会社 | 複素環化合物 |
US20140045856A1 (en) | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
EP2975031A4 (en) | 2013-03-14 | 2017-04-19 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
EP3018126A4 (en) | 2013-07-03 | 2016-12-07 | Takeda Pharmaceuticals Co | HETEROCYCLIC COMPOUND |
ES2950424T3 (es) | 2013-07-03 | 2023-10-09 | Takeda Pharmaceuticals Co | Compuesto de amida |
EP3091983B1 (en) | 2014-01-08 | 2019-10-02 | Intra-Cellular Therapies, Inc. | Pharmaceutical compositions comprising a pde-1 inhibitor and a pde-2 inhibitor |
CN103694244B (zh) * | 2014-01-09 | 2016-03-30 | 郑州大学 | 3,6位取代-1,2,4-三氮唑并[3,4-a]酞嗪类化合物及其制备和用途 |
US9932345B2 (en) | 2014-04-23 | 2018-04-03 | Dart Neuroscience (Cayman) Ltd. | Substituted [1,2,4]triazolo[1,5-A]pyrimidin-7-yl compounds as PDE2 inhibitors |
WO2016073424A1 (en) | 2014-11-05 | 2016-05-12 | Dart Neuroscience, Llc | Substituted 5-methyl-[1, 2, 4] triazolo [1,5-a) pyrimidin-2-amine compounds as pde2 inhibitors |
JP6608933B2 (ja) | 2014-12-06 | 2019-11-20 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
US10300064B2 (en) | 2014-12-06 | 2019-05-28 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2016145614A1 (en) * | 2015-03-17 | 2016-09-22 | Merck Sharp & Dohme Corp. | Triazolyl pyrimidinone compounds as pde2 inhibitors |
EP3285581B1 (en) | 2015-03-26 | 2021-08-11 | Merck Sharp & Dohme Corp. | Pyrazolyl pyrimidinone compounds as pde2 inhibitors |
WO2016179059A1 (en) | 2015-05-05 | 2016-11-10 | Merck Sharp & Dohme Corp. | Heteroaryl-pyrimidinone compounds as pde2 inhibitors |
WO2016183741A1 (en) | 2015-05-15 | 2016-11-24 | Merck Sharp & Dohme Corp. | Pyrimidinone amide compounds as pde2 inhibitors |
WO2016191935A1 (en) | 2015-05-29 | 2016-12-08 | Merck Sharp & Dohme Corp. | 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
WO2016192083A1 (en) | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
WO2016209749A1 (en) | 2015-06-25 | 2016-12-29 | Merck Sharp & Dohme Corp. | Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors |
WO2017000277A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Substituted triazolo bicycliccompounds as pde2 inhibitors |
WO2017000276A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic compounds as pde2 inhibitors |
EP3156405A1 (en) | 2015-10-13 | 2017-04-19 | Boehringer Ingelheim International GmbH | Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide |
EP3713572A1 (en) | 2017-11-23 | 2020-09-30 | Oslo University Hospital HF | Treatment of tachycardia |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI81350C (fi) * | 1982-01-18 | 1990-10-10 | Lepetit Spa | Analogfoerfarande foer framstaellning av nya, farmakologiskt aktiva 6-substituerade s-triatsolo/3,4-a/ ftalazinderivat. |
IT1194310B (it) * | 1983-07-12 | 1988-09-14 | Lepetit Spa | Derivati triazolo (3,4-a) ftalazinici 3,6-disostituiti |
US5869486A (en) * | 1995-02-24 | 1999-02-09 | Ono Pharmaceutical Co., Ltd. | Fused pyrimidines and pyriazines as pharmaceutical compounds |
HUP0600527A2 (en) | 1996-07-25 | 2006-11-28 | Merck Sharp & Dohme | Substituted triazolo-pyridazine derivatives as ligands for gaba receptors, process for their preparation and pharmaceutical compositions containing them |
CA2288789C (en) | 1997-05-08 | 2009-07-21 | Merck Sharp & Dohme Limited | Substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives as gaba alpha 5 ligands |
US6235741B1 (en) * | 1997-05-30 | 2001-05-22 | Merck & Co., Inc. | Angiogenesis inhibitors |
GB9715977D0 (en) * | 1997-07-29 | 1997-10-01 | Merck Sharp & Dohme | Therapeutic agents |
IT1303272B1 (it) * | 1998-10-29 | 2000-11-06 | Zambon Spa | Derivati triciclici inibitori della fosfodiesterasi 4 |
CA2395410A1 (en) | 1999-12-24 | 2001-07-05 | Bayer Aktiengesellschaft | Triazolotriazinones and the use thereof |
GB0028583D0 (en) * | 2000-11-23 | 2001-01-10 | Merck Sharp & Dohme | Therapeutic compounds |
US6958334B2 (en) * | 2001-04-10 | 2005-10-25 | Merck & Co., Inc. | Inhibitors of Akt activity |
TW200412966A (en) | 2002-09-04 | 2004-08-01 | Schering Corp | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US20070179161A1 (en) | 2003-03-31 | 2007-08-02 | Vernalis (Cambridge) Limited. | Pyrazolopyrimidine compounds and their use in medicine |
KR101368093B1 (ko) * | 2004-09-02 | 2014-03-14 | 다케다 게엠베하 | 트리아졸로프탈라진 |
KR20070095986A (ko) | 2005-01-05 | 2007-10-01 | 니코메드 게엠베하 | Pde2 억제제로서의 트리아졸로프탈라진 |
CA2591991C (en) | 2005-01-05 | 2013-11-19 | Altana Pharma Ag | Triazolophthalazines |
-
2006
- 2006-01-04 KR KR1020077017407A patent/KR20070095986A/ko not_active Application Discontinuation
- 2006-01-04 MX MX2007008137A patent/MX2007008137A/es active IP Right Grant
- 2006-01-04 US US11/794,145 patent/US8106047B2/en not_active Expired - Fee Related
- 2006-01-04 EP EP06700240A patent/EP1836207B1/en active Active
- 2006-01-04 BR BRPI0606379-9A patent/BRPI0606379A2/pt not_active IP Right Cessation
- 2006-01-04 ES ES06700240T patent/ES2397080T3/es active Active
- 2006-01-04 WO PCT/EP2006/050041 patent/WO2006072615A2/en active Application Filing
- 2006-01-04 CA CA2592007A patent/CA2592007C/en not_active Expired - Fee Related
- 2006-01-04 AU AU2006204454A patent/AU2006204454B2/en not_active Ceased
- 2006-01-04 CN CN2006800017646A patent/CN101103033B/zh not_active Expired - Fee Related
- 2006-01-04 EA EA200701396A patent/EA012505B1/ru not_active IP Right Cessation
- 2006-01-04 NZ NZ555661A patent/NZ555661A/en not_active IP Right Cessation
- 2006-01-04 JP JP2007548843A patent/JP5240899B2/ja not_active Expired - Fee Related
-
2007
- 2007-06-14 IL IL183919A patent/IL183919A/en not_active IP Right Cessation
- 2007-07-26 NO NO20073921A patent/NO20073921L/no not_active Application Discontinuation
-
2008
- 2008-06-30 HK HK08107251.1A patent/HK1116776A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20070095986A (ko) | 2007-10-01 |
BRPI0606379A2 (pt) | 2009-06-23 |
NZ555661A (en) | 2010-11-26 |
IL183919A (en) | 2011-06-30 |
EP1836207B1 (en) | 2012-10-10 |
CA2592007C (en) | 2013-12-10 |
CA2592007A1 (en) | 2006-07-13 |
US8106047B2 (en) | 2012-01-31 |
CN101103033A (zh) | 2008-01-09 |
EP1836207A2 (en) | 2007-09-26 |
EA012505B1 (ru) | 2009-10-30 |
MX2007008137A (es) | 2007-07-19 |
AU2006204454B2 (en) | 2011-11-10 |
WO2006072615A2 (en) | 2006-07-13 |
WO2006072615A3 (en) | 2007-01-04 |
EA200701396A1 (ru) | 2007-12-28 |
NO20073921L (no) | 2007-07-26 |
HK1116776A1 (en) | 2009-01-02 |
JP5240899B2 (ja) | 2013-07-17 |
ES2397080T3 (es) | 2013-03-04 |
JP2008526717A (ja) | 2008-07-24 |
US20080312225A1 (en) | 2008-12-18 |
IL183919A0 (en) | 2007-10-31 |
AU2006204454A1 (en) | 2006-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101103033B (zh) | 作为pde2抑制剂的***并酞嗪 | |
EP1557168B1 (en) | Biarylurea Derivatives | |
CN101133057B (zh) | ***并酞嗪化合物 | |
JP5130053B2 (ja) | トリアゾロフタラジン | |
EP1043998B1 (en) | USE OF PYRAZOLO [3,4-b] PYRIDINE AS CYCLIN DEPENDANT KINASE INHIBITORS | |
EP3589625B1 (en) | Isoquinolin and naphthydrin compounds | |
EP2872509B1 (en) | Inhibition of enzymes | |
CA2881045A1 (en) | Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b. | |
JP2008540391A (ja) | ピラゾリルアミノ置換ピリミジン、および癌の処置におけるそれらの使用 | |
CA3115088A1 (en) | Tyk2 inhibitors and uses thereof | |
US20090227648A1 (en) | Pyrazole derivatives useful for the treatment of cancer | |
CZ293825B6 (cs) | ChinoxalinyŹ způsob jejich výroby a jejich použití a farmaceutické prostředky tyto látky obsahující | |
CN101827820A (zh) | 氨基吡唑酰胺衍生物 | |
EP3661935B1 (en) | Substituted pyrazolopyrimidines useful as kinases inhibitors | |
Dou et al. | Rational modification, synthesis and biological evaluation of 3, 4-dihydroquinoxalin-2 (1H)-one derivatives as potent and selective c-Jun N-terminal kinase 3 (JNK3) inhibitors | |
WO2002002550A1 (fr) | Nouveaux derives pyrazinone | |
CN103168041A (zh) | 3,4-二氢吡咯并[1,2-a]吡嗪-2,8(1h)-二甲酰胺衍生物、其制备方法及其治疗用途 | |
EP3126354B1 (en) | Halogenated quinazolin-thf-amines as pde1 inhibitors | |
WO2005113550A1 (ja) | アミノピリミジン誘導体及びその医薬としての用途 | |
US20080261974A1 (en) | Novel Chemical Compounds | |
WO2008021725A2 (en) | Chemical compounds | |
Monge et al. | New 5H-pyridazino [4, 5-b] indole derivatives. Synthesis and studies as inhibitors of blood platelet aggregation and inotropics | |
WO2016127455A1 (zh) | 嘧啶衍生物、细胞毒性剂、药物组合物及其应用 | |
Liu et al. | Design, synthesis and broad-spectrum Bcr-Abl inhibitory activity of novel thiazolamide–benzamide derivatives | |
CN113004284B (zh) | 作为血浆激肽释放酶抑制剂的四环类化合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1116776 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1116776 Country of ref document: HK |
|
C56 | Change in the name or address of the patentee |
Owner name: NYCOMED INC. Free format text: FORMER NAME: NYCOMED GMBH |
|
CP01 | Change in the name or title of a patent holder |
Address after: Konstanz Patentee after: Nycomed GmbH Address before: Konstanz Patentee before: Nycomed GmbH |
|
C56 | Change in the name or address of the patentee |
Owner name: TAKEDA GMBH Free format text: FORMER NAME: NYCOMED INC. |
|
CP01 | Change in the name or title of a patent holder |
Address after: Konstanz Patentee after: Nycomed GmbH Address before: Konstanz Patentee before: Nycomed GmbH |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100804 Termination date: 20160104 |
|
EXPY | Termination of patent right or utility model |